+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Thyroid Eye Disease Treatments Market - Global Forecast to 2030- Product Image
Thyroid Eye Disease Treatments Market - Global Forecast to 2030- Product Image
Sale

Thyroid Eye Disease Treatments Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 191 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5012989
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Thyroid Eye Disease Treatments Market grew from USD 2.67 billion in 2024 to USD 2.83 billion in 2025. It is expected to continue growing at a CAGR of 5.94%, reaching USD 3.78 billion by 2030.

The Thyroid Eye Disease (TED) treatment landscape has undergone significant evolution over the past decade, driven by advances in immunology, surgical techniques, and patient-centric care models. Once considered a condition with limited therapeutic options confined largely to corticosteroids and decompressive surgeries, TED now benefits from an expanding arsenal of targeted biologics, precision diagnostics, and novel administration routes. This executive summary provides decision-makers with a clear, concise overview of current market dynamics and emerging trends. As healthcare stakeholders seek to balance clinical efficacy, safety, and cost-effectiveness, understanding the complex interplay between treatment modalities, regulatory environments, and competitive strategies has become imperative. The following sections delve into transformative shifts reshaping therapy paradigms, analyze the cumulative impact of proposed U.S. tariffs in 2025, and highlight segmentation, regional, and key company insights. By synthesizing these dimensions, this document aims to equip experts with actionable intelligence for strategic planning, investment prioritization, and partnership development in the rapidly evolving TED ecosystem.

Transformative Shifts Reshaping the Thyroid Eye Disease Treatment Landscape

The TED treatment arena is experiencing transformative shifts powered by scientific breakthroughs and evolving patient expectations. Foremost among these changes is the rise of targeted monoclonal antibodies that address specific inflammatory pathways, offering improved safety and tolerability compared to broad-spectrum corticosteroids. At the same time, advances in tyrosine kinase inhibitors and immunosuppressants have introduced alternative medical treatments, reducing dependency on high-dose steroid regimens. Concurrently, surgical innovation in orbital decompression and eyelid surgery has moved towards minimally invasive techniques, shortening recovery times and enhancing functional outcomes. Beyond the therapies themselves, digital health platforms enabling remote ocular assessments and real-time patient monitoring are gaining traction, fostering adherence and early intervention. Regulatory bodies are responding by streamlining approval pathways for breakthrough designations and real-world evidence submissions, reflecting a shift towards value-based healthcare. Moreover, personalized medicine approaches-such as stratifying patients by disease subtypes and biomarker profiles-are improving prognostic accuracy and informing tailored treatment protocols. Collectively, these shifts are redefining standards of care, intensifying competition, and opening new avenues for collaboration between pharmaceutical, surgical device, and digital health stakeholders.

Cumulative Impact of United States Tariffs on Thyroid Eye Disease Therapies in 2025

The proposed United States tariffs set to take effect in 2025 carry multifaceted implications for the TED therapy market. Heightened import duties on active pharmaceutical ingredients and biologic components risk driving up manufacturing costs, potentially translating into higher prices for monoclonal antibodies and kinase inhibitors. In response, manufacturers may accelerate local production initiatives or forge strategic alliances with domestic partners to mitigate tariff exposure and secure supply chains. At the same time, payers under pressure to contain healthcare spending could intensify scrutiny of high-cost therapies, prompting more stringent prior-authorization protocols and value-based contracting models. Meanwhile, surgical device suppliers face similar cost headwinds, encouraging them to optimize sourcing strategies and explore near-shoring opportunities. From a regulatory standpoint, government agencies and industry associations are likely to engage in active dialogue to seek exemptions or phased implementations for critical therapies. These dynamics underscore the need for flexible pricing strategies, diversified manufacturing footprints, and proactive policy advocacy. Ultimately, companies that anticipate tariff impacts and adapt their commercial and operational frameworks will be better positioned to maintain access, manage margins, and uphold patient care standards.

Key Segmentation Insights for Thyroid Eye Disease Treatments

A nuanced understanding of market segmentation illuminates key growth drivers and unmet needs across the TED treatment continuum. Based on treatment type, distinct trajectories emerge: medical interventions encompassing corticosteroids, immunosuppressants, monoclonal antibodies, thyroid hormone control, and tyrosine kinase inhibitors are transforming pharmacotherapy, while surgical approaches such as eyelid surgery, orbital decompression surgery, and strabismus surgery continue to refine functional and aesthetic outcomes. Considering route of administration, intravenous infusions offer rapid systemic exposure for severe inflammatory cases, while oral formulations deliver patient convenience and improved compliance, and topical therapies provide localized relief with reduced systemic risk. Classification by disease type reveals divergent pathways for Type I TED, typically characterized by eyelid retraction and conjunctival inflammation, versus the more severe Type II TED, which involves compressive optic neuropathy. Diagnostic approaches-from blood tests assessing thyroid antibodies and inflammatory markers to imaging studies, orbital ultrasound, and radioactive iodine uptake tests-ensure precise staging and inform therapeutic sequencing. End-user dynamics highlight the critical roles of hospitals in managing acute presentations, outpatient centers in delivering day-case infusions, and specialty clinics in providing multidisciplinary care. Finally, distribution channels through hospital pharmacies, online pharmacies, and retail outlets shape product accessibility and patient adherence. Integrating these segmentation insights enables stakeholders to align R&D investments, optimize commercial tactics, and tailor service models for diverse patient cohorts.

Regional Dynamics Influencing the Thyroid Eye Disease Treatment Market

Regional dynamics exert a profound influence on TED treatment adoption, shaped by varying healthcare infrastructures, regulatory frameworks, and reimbursement environments. In the Americas, established healthcare systems and progressive reimbursement policies facilitate rapid uptake of high-cost biologics and cutting-edge surgical devices, while robust clinical trial networks accelerate evidence generation. Europe, the Middle East & Africa exhibit heterogeneity: Western European markets embrace value-based assessments and conditional approvals, whereas emerging markets in Eastern Europe, the Gulf, and Africa wrestle with budget constraints and infrastructure gaps, creating opportunities for cost-effective generics and biosimilars. In the Asia-Pacific region, expanding healthcare investment, rising patient awareness, and government initiatives to enhance access propel market growth; however, fragmented regulatory processes across countries call for tailored market entry strategies. Cross-regional partnerships, hub-and-spoke distribution models, and tiered pricing frameworks are proving instrumental in bridging access disparities. Navigating these regional nuances will be crucial for companies seeking to optimize launch sequencing, allocate resources strategically, and foster meaningful collaborations with local stakeholders.

Competitive Landscape and Key Company Strategies

The competitive landscape is characterized by a blend of established pharmaceutical giants and innovative biotechs vying for leadership in the TED arena. Abbott Laboratories and AbbVie Inc. continue to leverage their immunology expertise to advance monoclonal antibody candidates, while ACELYRIN, Inc. and Amgen Inc. invest in next-generation tyrosine kinase inhibitors. Argenx SE and Immunovant, Inc. are driving clinical innovation with first-in-class antibody therapies targeting novel inflammatory pathways. Bausch & Lomb Incorporated and BioXpress Therapeutics SA are at the forefront of ophthalmic-focused delivery systems, enhancing topical treatment efficacy. Broad-based players such as Biocon Limited, Cipla Limited, Dr. Reddy’s Laboratories Ltd., and Lupin Limited are positioning biosimilars to address cost pressures, particularly in emerging economies. Eli Lilly and Company, F. Hoffmann-La Roche AG, Genmab A/S, GlaxoSmithKline PLC, H. Lundbeck A/S, and Merck KGaA bring robust pipelines in both medical and surgical adjuncts, supporting combination therapy regimens. Intas Pharmaceuticals Ltd. and Teva Pharmaceutical Industries Ltd. capitalize on manufacturing scale to supply generic corticosteroids and immunosuppressants. Johnson & Johnson Services Inc., Novartis AG, Pfizer, Inc., and Regeneron Pharmaceuticals, Inc. collaborate on strategic alliances that blend R&D prowess with commercialization networks. Sling Therapeutics, Inc. and Viridian Therapeutics, Inc. underscore the rising impact of smaller biotechs, rapidly advancing precision therapies through agile development models. Amidst these dynamics, companies must continuously refine their portfolios, pursue synergistic partnerships, and demonstrate differentiated value to secure competitive advantage.

Actionable Recommendations for Industry Leaders

In this evolving environment, industry leaders should adopt a multifaceted strategy to capture value and drive sustainable growth. First, accelerating investment in targeted biologics and next-generation small molecules will address unmet needs while reinforcing differentiation from generic offerings. Second, diversifying manufacturing and sourcing through regional hubs and contract manufacturing organizations can mitigate tariff impacts and fortify supply resilience. Third, embracing digital health solutions-such as AI-driven diagnostic algorithms and remote monitoring platforms-will enhance patient engagement and provide real-world evidence to support reimbursement discussions. Fourth, forging strategic alliances with academic centers, specialty clinics, and patient advocacy groups will facilitate co-creation of patient-centric care pathways and bolster brand credibility. Fifth, implementing flexible pricing and value-based contracting models aligned with clinical outcomes will satisfy payer demands and safeguard access. Sixth, focusing clinical development on combination regimens and personalized medicine approaches, informed by biomarker stratification, will optimize therapeutic efficacy and market receptivity. Seventh, expanding presence in under-penetrated regions through tiered pricing, local partnerships, and capacity building initiatives will unlock new growth corridors. By executing these recommendations, industry leaders can strengthen their competitive positioning, accelerate innovation adoption, and deliver superior patient outcomes.

Conclusion and Future Outlook

The Thyroid Eye Disease treatment market stands at a pivotal juncture, propelled by scientific advancements and reshaped by evolving policy landscapes. Stakeholders who proactively align their development portfolios with patient needs, fortify supply chains against geopolitical headwinds, and leverage data-driven approaches to demonstrate value will define the next era of care. Collaboration across the ecosystem-from biotech innovators to healthcare providers and payers-will be instrumental in overcoming access barriers and translating clinical breakthroughs into real-world impact. As novel therapies gain regulatory approval and digital health integration accelerates, the industry must remain agile, evidence-focused, and patient-centered to realize the full potential of emerging treatment paradigms.

Market Segmentation & Coverage

This research report categorizes the Thyroid Eye Disease Treatments Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Medical Treatment
    • Corticosteroids
    • Immunosuppressants
    • Monoclonal Antibodies
    • Thyroid Hormone Control
    • Tyrosine Kinase Inhibitors
  • Surgical Treatment
    • Eyelid Surgery
    • Orbital Decompression Surgery
    • Strabismus Surgery
  • Intravenous
  • Oral
  • Topical
  • Type I TED
  • Type II TED
  • Blood Test
  • Imaging Test
  • Orbital Ultrasound
  • Radioactive Iodine Uptake Test
  • Hospitals
  • Outpatient Centers
  • Specialty Clinics
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

This research report categorizes the Thyroid Eye Disease Treatments Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • Massachusetts
      • New Jersey
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Thyroid Eye Disease Treatments Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Abbott Laboratories
  • AbbVie Inc.
  • ACELYRIN, INC.
  • Amgen Inc.
  • argenx SE
  • Bausch & Lomb Incorporated
  • Biocon Limited
  • BioXpress Therapeutics SA
  • Cipla Limited
  • Dr. Reddy’s Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Genmab A/S
  • GlaxoSmithKline PLC
  • H. Lundbeck A/S
  • Hetero Drugs Limited
  • Immunovant, Inc.
  • Intas Pharmaceuticals Ltd.
  • Johnson & Johnson Services Inc.
  • Lupin Limited
  • Merck KGaA
  • Novartis AG
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sling Therapeutics, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viridian Therapeutics, Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Thyroid Eye Disease Treatments Market, by Treatment Type
8.1. Introduction
8.2. Medical Treatment
8.2.1. Corticosteroids
8.2.2. Immunosuppressants
8.2.3. Monoclonal Antibodies
8.2.4. Thyroid Hormone Control
8.2.5. Tyrosine Kinase Inhibitors
8.3. Surgical Treatment
8.3.1. Eyelid Surgery
8.3.2. Orbital Decompression Surgery
8.3.3. Strabismus Surgery
9. Thyroid Eye Disease Treatments Market, by Route of Administration
9.1. Introduction
9.2. Intravenous
9.3. Oral
9.4. Topical
10. Thyroid Eye Disease Treatments Market, by Type
10.1. Introduction
10.2. Type I TED
10.3. Type II TED
11. Thyroid Eye Disease Treatments Market, by Diagnosis
11.1. Introduction
11.2. Blood Test
11.3. Imaging Test
11.4. Orbital Ultrasound
11.5. Radioactive Iodine Uptake Test
12. Thyroid Eye Disease Treatments Market, by End-User
12.1. Introduction
12.2. Hospitals
12.3. Outpatient Centers
12.4. Specialty Clinics
13. Thyroid Eye Disease Treatments Market, by Distribution
13.1. Introduction
13.2. Hospital Pharmacy
13.3. Online Pharmacy
13.4. Retail Pharmacy
14. Americas Thyroid Eye Disease Treatments Market
14.1. Introduction
14.2. Argentina
14.3. Brazil
14.4. Canada
14.5. Mexico
14.6. United States
15. Asia-Pacific Thyroid Eye Disease Treatments Market
15.1. Introduction
15.2. Australia
15.3. China
15.4. India
15.5. Indonesia
15.6. Japan
15.7. Malaysia
15.8. Philippines
15.9. Singapore
15.10. South Korea
15.11. Taiwan
15.12. Thailand
15.13. Vietnam
16. Europe, Middle East & Africa Thyroid Eye Disease Treatments Market
16.1. Introduction
16.2. Denmark
16.3. Egypt
16.4. Finland
16.5. France
16.6. Germany
16.7. Israel
16.8. Italy
16.9. Netherlands
16.10. Nigeria
16.11. Norway
16.12. Poland
16.13. Qatar
16.14. Russia
16.15. Saudi Arabia
16.16. South Africa
16.17. Spain
16.18. Sweden
16.19. Switzerland
16.20. Turkey
16.21. United Arab Emirates
16.22. United Kingdom
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Abbott Laboratories
17.3.2. AbbVie Inc.
17.3.3. ACELYRIN, INC.
17.3.4. Amgen Inc.
17.3.5. argenx SE
17.3.6. Bausch & Lomb Incorporated
17.3.7. Biocon Limited
17.3.8. BioXpress Therapeutics SA
17.3.9. Cipla Limited
17.3.10. Dr. Reddy’s Laboratories Ltd.
17.3.11. Eli Lilly and Company
17.3.12. F. Hoffmann-La Roche AG
17.3.13. Genmab A/S
17.3.14. GlaxoSmithKline PLC
17.3.15. H. Lundbeck A/S
17.3.16. Hetero Drugs Limited
17.3.17. Immunovant, Inc.
17.3.18. Intas Pharmaceuticals Ltd.
17.3.19. Johnson & Johnson Services Inc.
17.3.20. Lupin Limited
17.3.21. Merck KGaA
17.3.22. Novartis AG
17.3.23. Pfizer, Inc.
17.3.24. Regeneron Pharmaceuticals, Inc.
17.3.25. Sling Therapeutics, Inc.
17.3.26. Teva Pharmaceutical Industries Ltd.
17.3.27. Viridian Therapeutics, Inc.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. THYROID EYE DISEASE TREATMENTS MARKET MULTI-CURRENCY
FIGURE 2. THYROID EYE DISEASE TREATMENTS MARKET MULTI-LANGUAGE
FIGURE 3. THYROID EYE DISEASE TREATMENTS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2024 VS 2030 (%)
FIGURE 14. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2024 VS 2030 (%)
FIGURE 18. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. THYROID EYE DISEASE TREATMENTS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. THYROID EYE DISEASE TREATMENTS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. THYROID EYE DISEASE TREATMENTS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY THYROID HORMONE CONTROL, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY EYELID SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ORBITAL DECOMPRESSION SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY STRABISMUS SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE I TED, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE II TED, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY BLOOD TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY IMAGING TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ORBITAL ULTRASOUND, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY RADIOACTIVE IODINE UPTAKE TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY OUTPATIENT CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 48. ARGENTINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 49. ARGENTINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 50. ARGENTINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 51. ARGENTINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 52. ARGENTINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 53. ARGENTINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 54. ARGENTINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 55. ARGENTINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 56. BRAZIL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 57. BRAZIL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 58. BRAZIL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 59. BRAZIL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 60. BRAZIL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 61. BRAZIL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 62. BRAZIL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 63. BRAZIL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 64. CANADA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 65. CANADA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 66. CANADA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 67. CANADA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 68. CANADA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 69. CANADA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 70. CANADA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 71. CANADA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 72. MEXICO THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 73. MEXICO THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 74. MEXICO THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 75. MEXICO THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 76. MEXICO THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 77. MEXICO THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 78. MEXICO THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 79. MEXICO THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 89. ASIA-PACIFIC THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 90. ASIA-PACIFIC THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 91. ASIA-PACIFIC THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 92. ASIA-PACIFIC THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 93. ASIA-PACIFIC THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 94. ASIA-PACIFIC THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 95. ASIA-PACIFIC THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 96. ASIA-PACIFIC THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 97. ASIA-PACIFIC THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 98. AUSTRALIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 99. AUSTRALIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 100. AUSTRALIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 101. AUSTRALIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 102. AUSTRALIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 103. AUSTRALIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 104. AUSTRALIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 105. AUSTRALIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 106. CHINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 107. CHINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 108. CHINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 109. CHINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 110. CHINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 111. CHINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 112. CHINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 113. CHINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 114. INDIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 115. INDIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 116. INDIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 117. INDIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 118. INDIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 119. INDIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 120. INDIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 121. INDIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 122. INDONESIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 123. INDONESIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 124. INDONESIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 125. INDONESIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 126. INDONESIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 127. INDONESIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 128. INDONESIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 129. INDONESIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 130. JAPAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 131. JAPAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 132. JAPAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 133. JAPAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 134. JAPAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 135. JAPAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 136. JAPAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 137. JAPAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 138. MALAYSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 139. MALAYSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 140. MALAYSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 141. MALAYSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 142. MALAYSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 143. MALAYSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 144. MALAYSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 145. MALAYSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 146. PHILIPPINES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 147. PHILIPPINES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 148. PHILIPPINES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 149. PHILIPPINES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 150. PHILIPPINES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 151. PHILIPPINES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 152. PHILIPPINES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 153. PHILIPPINES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 154. SINGAPORE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 155. SINGAPORE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 156. SINGAPORE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 157. SINGAPORE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 158. SINGAPORE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 159. SINGAPORE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 160. SINGAPORE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 161. SINGAPORE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 162. SOUTH KOREA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 163. SOUTH KOREA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 164. SOUTH KOREA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 165. SOUTH KOREA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 166. SOUTH KOREA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 167. SOUTH KOREA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 168. SOUTH KOREA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 169. SOUTH KOREA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 170. TAIWAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 171. TAIWAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 172. TAIWAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 173. TAIWAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 174. TAIWAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 175. TAIWAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 176. TAIWAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 177. TAIWAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 178. THAILAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 179. THAILAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 180. THAILAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 181. THAILAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 182. THAILAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 183. THAILAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 184. THAILAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 185. THAILAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 186. VIETNAM THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 187. VIETNAM THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 188. VIETNAM THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 189. VIETNAM THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 190. VIETNAM THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 191. VIETNAM THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 192. VIETNAM THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 193. VIETNAM THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 203. DENMARK THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 204. DENMARK THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 205. DENMARK THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 206. DENMARK THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 207. DENMARK THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 208. DENMARK THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 209. DENMARK THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 210. DENMARK THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 211. EGYPT THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 212. EGYPT THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 213. EGYPT THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 214. EGYPT THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 215. EGYPT THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 216. EGYPT THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 217. EGYPT THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 218. EGYPT THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 219. FINLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 220. FINLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 221. FINLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 222. FINLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 223. FINLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 224. FINLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 225. FINLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 226. FINLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 227. FRANCE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 228. FRANCE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 229. FRANCE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 230. FRANCE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 231. FRANCE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 232. FRANCE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 233. FRANCE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 234. FRANCE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 235. GERMANY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 236. GERMANY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 237. GERMANY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 238. GERMANY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 239. GERMANY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 240. GERMANY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 241. GERMANY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 242. GERMANY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 243. ISRAEL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 244. ISRAEL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 245. ISRAEL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 246. ISRAEL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 247. ISRAEL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 248. ISRAEL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 249. ISRAEL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 250. ISRAEL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 251. ITALY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 252. ITALY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 253. ITALY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 254. ITALY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 255. ITALY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 256. ITALY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 257. ITALY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 258. ITALY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 259. NETHERLANDS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 260. NETHERLANDS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 261. NETHERLANDS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 262. NETHERLANDS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 263. NETHERLANDS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 264. NETHERLANDS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 265. NETHERLANDS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 266. NETHERLANDS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 267. NIGERIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 268. NIGERIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 269. NIGERIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 270. NIGERIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 271. NIGERIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 272. NIGERIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 273. NIGERIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 274. NIGERIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 275. NORWAY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 276. NORWAY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 277. NORWAY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 278. NORWAY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 279. NORWAY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 280. NORWAY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 281. NORWAY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 282. NORWAY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 283. POLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 284. POLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 285. POLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 286. POLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 287. POLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 288. POLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 289. POLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 290. POLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 291. QATAR THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 292. QATAR THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 293. QATAR THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 294. QATAR THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 295. QATAR THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 296. QATAR THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 297. QATAR THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 298. QATAR THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 299. RUSSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 300. RUSSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 301. RUSSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 302. RUSSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 303. RUSSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 304. RUSSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 305. RUSSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 306. RUSSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 307. SAUDI ARABIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 308. SAUDI ARABIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)

Companies Mentioned

  • Abbott Laboratories
  • AbbVie Inc.
  • ACELYRIN, INC.
  • Amgen Inc.
  • argenx SE
  • Bausch & Lomb Incorporated
  • Biocon Limited
  • BioXpress Therapeutics SA
  • Cipla Limited
  • Dr. Reddy’s Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Genmab A/S
  • GlaxoSmithKline PLC
  • H. Lundbeck A/S
  • Hetero Drugs Limited
  • Immunovant, Inc.
  • Intas Pharmaceuticals Ltd.
  • Johnson & Johnson Services Inc.
  • Lupin Limited
  • Merck KGaA
  • Novartis AG
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sling Therapeutics, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viridian Therapeutics, Inc.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Global Thyroid Eye Disease Treatment Market (2025 Edition): Analysis By Therapeutic Type (Monoclonal Antibodies, Corticosteroids, Vitamins, and Other Therapies), Route of Administration, Distribution Channel: Market Insights and Forecast (2021-2031) - Product Image

Global Thyroid Eye Disease Treatment Market (2025 Edition): Analysis By Therapeutic Type (Monoclonal Antibodies, Corticosteroids, Vitamins, and Other Therapies), Route of Administration, Distribution Channel: Market Insights and Forecast (2021-2031)

  • Report
  • 238 Pages
  • Global
From
Thyroid Eye Disease (TED) - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Thyroid Eye Disease (TED) - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Graves' Ophthalmopathy - Pipeline Insight, 2025 - Product Image

Graves' Ophthalmopathy - Pipeline Insight, 2025

  • Clinical Trials
  • 80 Pages
  • Global
From
Diabetic Eye Disease Devices Market - Global Forecast to 2030 - Product Image

Diabetic Eye Disease Devices Market - Global Forecast to 2030

  • Report
  • 198 Pages
  • Global
From
Dry Eye Disease Treatment Devices Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

Dry Eye Disease Treatment Devices Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 183 Pages
  • Global
From

About the Thyroid Eye Disease Treatment Market

Thyroid Eye Disease (TED) is a rare autoimmune disorder that affects the eyes and surrounding tissues. It is caused by an overactive thyroid gland, which produces antibodies that attack the muscles and fatty tissues around the eyes. Symptoms of TED include bulging eyes, double vision, and dry eyes. Treatment for TED typically involves a combination of medications, surgery, and lifestyle changes. Medications used to treat TED include corticosteroids, immunosuppressants, and antithyroid drugs. Surgery may be used to correct double vision, reduce the bulging of the eyes, and improve the appearance of the eyes. Lifestyle changes such as avoiding smoking, reducing stress, and eating a healthy diet can also help manage the symptoms of TED. Companies in the Thyroid Eye Disease Treatment market include Allergan, Novartis, Pfizer, and Regeneron. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.